Long-term drug survival of adalimumab, infliximab, secukinumab and ustekinumab in hidradenitis suppurativa: a Danish nationwide cohort study
Br J Dermatol
.
2024 Apr 17;190(5):769-771.
doi: 10.1093/bjd/ljae042.
Authors
Hans Christian Ring
1
,
Jonathan Thorsen
2
,
Brian Kirby
3
,
John R Ingram
4
,
Nana Aviaaja Lippert Rosenø
1
,
Nikolaj Holgersen
1
,
Valdemar W Nielsen
1
,
David Nikolai Thein Aagaard
1
,
Julia-Tatjana Maul
5
,
Jashin J Wu
6
,
Jacob P Thyssen
1
7
,
Alexander Egeberg
1
7
,
Simon F Thomsen
1
8
Affiliations
1
Department of Dermato-Venereology and Wound Healing Centre, Bispebjerg Hospital, Copenhagen, Denmark.
2
COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital.
3
The Charles Centre, Department of Dermatology, St. Vincent's University Hospital, Dublin, Ireland.
4
Department of Dermatology and Academic Wound Healing, Institute of Infection and Immunity, Cardiff University, Cardiff, UK.
5
Department of Dermatology, University of Zürich, Zürich, Switzerland.
6
Department of Dermatology, University of Miami Miller School of Medicine, Los Angeles, CA, USA.
7
Department of Clinical Medicine and.
8
Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
PMID:
38305415
DOI:
10.1093/bjd/ljae042
No abstract available
MeSH terms
Adalimumab
Antibodies, Monoclonal, Humanized*
Cohort Studies
Denmark
Hidradenitis Suppurativa*
Humans
Infliximab
Ustekinumab*
Substances
Adalimumab
Ustekinumab
Infliximab
secukinumab
Antibodies, Monoclonal, Humanized